Development of pharmaceutical products in nuclear medicine.
Radiotherapy is an efficient cancer treatment. External beam radiotherapy and radioactive implants are routinely used to destroy primary tumors and to prevent local and regional relapse.
Radioimmunotherapy (RIT) expands the use of radiotherapy to treat disseminated cancer by targeting injected radioactivity using antibodies as vectors. RIT is already approved for the treatment
of non-Hodgkin lymphoma. ATLAB Pharma aims to expand the use of RIT to treat major cancers